CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...